论文部分内容阅读
目的评价急性ST段抬高心肌梗死(STEMI)患者经皮冠状动脉介人治疗(PCI)术后应用替罗非班时间对住院期间预后的影响。方法从2006年1月-2006年12月,50例急性STEMI患者入院后均即刻接受替罗非班治疗,直接PCI治疗后即刻随机分为两组:短时间组(STG 29例,PCI术后替罗非班继续使用24～36h)和长时间组(LTG 21例,PCI术后替罗非班继续使用48～72h)。记录两组基础临床资料、造影资料、出血事件、住院期间主要心血管事件以及出院前心超评估的左心室射血分数。结果两组间的基础临床状况、造影资料、出血事件发生率差异均无统计学意义(P>0.05);但LTG组的住院期间心绞痛次数较STG组明显减少[(1.26±0.72)次/d比(1.75±0.88)次/d,P=0.040],且左心室射血分数明显好于STG组[(57.2±8.61%比(52.0±8.5)%;P=0.037]。结论急性STEMI患者急症PCI术后较长时间应用国产替罗非班是安全的,并可减少住院期间心绞痛发作次数以及改善左室射血分数。
Objective To evaluate the effect of tirofiban on the prognosis of patients with acute ST-elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). Methods From January 2006 to December 2006, 50 acute STEMI patients were treated with tirofiban immediately after admission. Immediate PCI was randomly divided into two groups: short-term group (29 cases of STG after PCI Tirofiban continued to use for 24-36 h) and long-term group (LTG 21 cases, continued use of tirofiban for 48-72 h after PCI). Two groups of basic clinical data, contrast data, bleeding events, major cardiovascular events during hospitalization, and left ventricular ejection fraction assessed before cardiac discharge were recorded. Results There was no significant difference in basic clinical status, contrast data and incidence of bleeding between the two groups (P> 0.05). However, the number of angina pectoris in LTG group was significantly lower than that in STG group [(1.26 ± 0.72) times / d (1.75 ± 0.88) times / d, P = 0.040], and left ventricular ejection fraction was significantly better than STG group (57.2 ± 8.61% vs 52.0 ± 8.5%, P = 0.037) .Conclusion The acute STEMI patients Long-term use of domestic tirofiban after PCI is safe, and can reduce the number of angina attacks during hospitalization and improve left ventricular ejection fraction.